# Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

> **NCT01863758** · PHASE3 · COMPLETED · sponsor: **Octapharma** · enrollment: 66 (actual)

## Conditions studied

- Severe Haemophilia A

## Interventions

- **BIOLOGICAL:** Human-cl rhFVIII

## Key facts

- **NCT ID:** NCT01863758
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2018-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863758, "Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01863758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*